SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology
Molecules · 25.07.2025 · 30 (15) · 3112
DOI: 10.3390/molecules30153112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 25.07.2025. Verfasst von Marlena Stielow und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 Jurasza St., 85-089 …. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Diabetes Mellitus, Type 2, Diabetes Mellitus. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Studies have shown that sodium-glucose cotransporter type 2 (SGLT2) inhibitors not only help lower blood glucose levels but also offer cardioprotective effects, reduce the progression of heart failure, and may even slow the progression of aortic stenosis. The mechanisms of these beneficial properties are thought to involve multiple pathways, including reducing inflammation, oxidative stress, and improving cellular energy metabolism. Advancing knowledge about the mechanisms of action of these drugs and their effects on the course of the aforementioned diseases has become the subject of intensive clinical and scientific research. This publication aims to provide insight into the role of SGLT2 inhibitors in the context of diabetes mellitus, heart failure and acute coronary syndrome, through clinical analysis, mechanistic insights and comparison of the effects of these drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Organic Chemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 Jurasza St., 85-089 Bydgoszcz, Poland.
- Department of Neurobiology and Biophysics, Institute of Bioscience, Vilnius University, Saulėtekio Ave. 7, LT-10257 Vilnius, Lithuania.
- Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 87-100 Toruń, Poland.
- Department of Paediatrics, Haematology and Oncology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 9 M. Curie Skłodowska St., 85-094 Bydgoszcz, Poland.
- Department of Physical Chemistry and Physicochemistry of Polymers, Faculty of Chemistry, Nicolaus Copernicus University in Toruń, 7 Gagarina St., 87-100 Toruń, Poland.
ORCID-Profile: Łukasz Fijałkowski, Aidas Alaburda, Grzegorz Grześk, Elżbieta Grześk, Jacek Nowaczyk, Alicja Nowaczyk
Zitieren
APA
Stielow, M., Fijałkowski, Ł., Alaburda, A., Grześk, G., Grześk, E., Nowaczyk, J., & Nowaczyk, A. (2025). SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. Molecules, 30(15), 3112. https://doi.org/10.3390/molecules30153112
Vancouver
Stielow M, Fijałkowski Ł, Alaburda A, Grześk G, Grześk E, Nowaczyk J, et al. SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology. Molecules. 2025;30(15):3112. doi:10.3390/molecules30153112
BibTeX
@article{Stielow2025,
author = {Stielow, Marlena and Fijałkowski, Łukasz and Alaburda, Aidas and Grześk, Grzegorz and Grześk, Elżbieta and Nowaczyk, Jacek and Nowaczyk, Alicja},
title = {SGLT2 Inhibitors: From Molecular Mechanisms to Clinical Outcomes in Cardiology and Diabetology},
journal = {Molecules},
year = {2025},
volume = {30},
number = {15},
pages = {3112},
doi = {10.3390/molecules30153112}
}
EUVIMED